Sulfide-modified nanoscale zero-valent iron as a novel therapeutic remedy for septic myocardial injury
Copyright © 2023. Production and hosting by Elsevier B.V..
INTRODUCTION: Myocardial injury is a serious complication in sepsis with high mortality. Zero-valent iron nanoparticles (nanoFe) displayed novel roles in cecal ligation and puncture (CLP)-induced septic mouse model. Nonetheless, its high reactivity makes it difficult for long-term storage.
OBJECTIVES: To overcome the obstacle and improve therapeutic efficiency, a surface passivation of nanoFe was designed using sodium sulfide.
METHODS: We prepared iron sulfide nanoclusters and constructed CLP mouse models. Then the effect of sulfide-modified nanoscale zero-valent iron (S-nanoFe) on the survival rate, blood routine parameters, blood biochemical parameters, cardiac function, and pathological indicators of myocardium was observed. RNA-seq was used to further explore the comprehensive protective mechanisms of S-nanoFe. Finally, the stability of S-nanoFe-1d and S-nanoFe-30 d, together with the therapeutic efficacy of sepsis between S-nanoFe and nanoFe was compared.
RESULTS: The results revealed that S-nanoFe significantly inhibited the growth of bacteria and exerted a protective role against septic myocardial injury. S-nanoFe treatment activated AMPK signaling and ameliorated several CLP-induced pathological processes including myocardial inflammation, oxidative stress, mitochondrial dysfunction. RNA-seq analysis further clarified the comprehensive myocardial protective mechanisms of S-nanoFe against septic injury. Importantly, S-nanoFe had a good stability and a comparable protective efficacy to nanoFe.
CONCLUSIONS: The surface vulcanization strategy for nanoFe has a significant protective role against sepsis and septic myocardial injury. This study provides an alternative strategy for overcoming sepsis and septic myocardial injury and opens up possibilities for the development of nanoparticle in infectious diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Journal of advanced research - 55(2024) vom: 26. Jan., Seite 145-158 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Daquan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AMPK |
|---|
| Anmerkungen: |
Date Completed 01.01.2024 Date Revised 08.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jare.2023.02.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353078344 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353078344 | ||
| 003 | DE-627 | ||
| 005 | 20240114231900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jare.2023.02.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM353078344 | ||
| 035 | |a (NLM)36801383 | ||
| 035 | |a (PII)S2090-1232(23)00058-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Daquan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sulfide-modified nanoscale zero-valent iron as a novel therapeutic remedy for septic myocardial injury |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2024 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Production and hosting by Elsevier B.V. | ||
| 520 | |a INTRODUCTION: Myocardial injury is a serious complication in sepsis with high mortality. Zero-valent iron nanoparticles (nanoFe) displayed novel roles in cecal ligation and puncture (CLP)-induced septic mouse model. Nonetheless, its high reactivity makes it difficult for long-term storage | ||
| 520 | |a OBJECTIVES: To overcome the obstacle and improve therapeutic efficiency, a surface passivation of nanoFe was designed using sodium sulfide | ||
| 520 | |a METHODS: We prepared iron sulfide nanoclusters and constructed CLP mouse models. Then the effect of sulfide-modified nanoscale zero-valent iron (S-nanoFe) on the survival rate, blood routine parameters, blood biochemical parameters, cardiac function, and pathological indicators of myocardium was observed. RNA-seq was used to further explore the comprehensive protective mechanisms of S-nanoFe. Finally, the stability of S-nanoFe-1d and S-nanoFe-30 d, together with the therapeutic efficacy of sepsis between S-nanoFe and nanoFe was compared | ||
| 520 | |a RESULTS: The results revealed that S-nanoFe significantly inhibited the growth of bacteria and exerted a protective role against septic myocardial injury. S-nanoFe treatment activated AMPK signaling and ameliorated several CLP-induced pathological processes including myocardial inflammation, oxidative stress, mitochondrial dysfunction. RNA-seq analysis further clarified the comprehensive myocardial protective mechanisms of S-nanoFe against septic injury. Importantly, S-nanoFe had a good stability and a comparable protective efficacy to nanoFe | ||
| 520 | |a CONCLUSIONS: The surface vulcanization strategy for nanoFe has a significant protective role against sepsis and septic myocardial injury. This study provides an alternative strategy for overcoming sepsis and septic myocardial injury and opens up possibilities for the development of nanoparticle in infectious diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AMPK | |
| 650 | 4 | |a Inflammatory response | |
| 650 | 4 | |a Myocardial injury | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a S-nanoFe | |
| 650 | 4 | |a Sepsis | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 650 | 7 | |a Sulfides |2 NLM | |
| 700 | 1 | |a Zhao, Huadong |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Wangrui |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shaofei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Wenwen |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Chenxi |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Lingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of advanced research |d 2013 |g 55(2024) vom: 26. Jan., Seite 145-158 |w (DE-627)NLM246273542 |x 2090-1224 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2024 |g day:26 |g month:01 |g pages:145-158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jare.2023.02.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2024 |b 26 |c 01 |h 145-158 | ||